Feb 16, 2018   SOURCE: PR NewsWire

Global Tumor Lysis Syndrome (TLS) Market 2017-2027

DUBLIN, Feb. 16, 2018 /PRNewswire/ --

The "Market Spotlight: Tumor Lysis Syndrome (TLS)" report has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key pipeline and marketed drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

    --  The author estimates that in 2016, there were approximately 12,300
        incident cases of tumor lysis syndrome (TLS) worldwide among individuals
        with high-risk malignancies (acute myeloid leukemia, acute lymphocytic
        leukemia, and Burkitt's lymphoma).
    --  The number of incident cases is forecasted to increase to 13,400 by
        2025. Marketed drugs for TLS comprise xanthine oxidase inhibitors such
        as Aloprim (allopurinol) and Uloric (febuxostat), as well as a
        recombinant urate oxidase enzyme, Elitek (rasburicase).
    --  Uloric is the only drug in active clinical development in the US for
        TLS. It targets xanthine oxidase, and is administered orally. There was
        only one licensing agreement involving cancer chemotherapy-induced TLS
        drugs during 2012-17. This deal was an exclusive distribution agreement
        between Teijin Pharma and Menarini Group for the marketing of Teijin
        Pharma's febuxostat in 26 additional countries. The value of the deal
        was not disclosed.
    --  The distribution of clinical trials across Phase I-IV indicates that the
        majority of trials for TLS have been in the late phase of development,
        with 66.6% in Phase III-IV and only 33.3% in Phase I-II.
    --  The US has a substantial lead in the number of TLS clinical trials
        globally. Clinical trial activity in the TLS space is dominated by
        completed trials. Sanofi has the highest number of completed clinical
        trials for TLS, with six in total.
    --  Sanofi has carried out the most clinical trials in the TLS space, with
        Menarini being the only other trial sponsor.

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
Prophylaxis and monitoring
Volume expansion
Medical therapies
Renal replacement therapy

EPIDEMIOLOGY
Incidence assumptions

MARKETED DRUGS
Approvals by country

PIPELINE DRUGS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/jmzqvp/global_tumor?w=5

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-tumor-lysis-syndrome-tls-market-2017-2027-300600007.html

SOURCE Research and Markets